Drug Discovery

The PhRMA Foundation’s Drug Discovery Targets and Pathways Program funds early-career academic scientists who are pioneering new approaches to drug discovery. We support research projects that have the potential to make a significant impact for patients. By funding drug discovery research by promising young scientists, the Foundation helps accelerate the identification of new therapeutic compounds and modalities while building a talent base to support innovation across the biopharmaceutical industry.

How are new drugs discovered and developed?

Discovering and developing new drugs is a multistage, interdisciplinary process that typically involves significant investments of time and resources from both academic researchers and the biopharmaceutical industry, often over a period of many years.

The earliest stages of drug discovery involve identifying potential molecular targets or pathways in the body that are believed to play a role in a particular disease. Researchers then identify compounds that interact with the targets in question and may offer a therapeutic benefit to patients suffering from the condition. These compounds are rigorously tested in preclinical models to understand how the drug candidate works and what potential side effects might be expected.

Upon completion of preclinical testing, drug sponsors request permission from the U.S. Food and Drug Administration to begin testing the drug in humans. Typically, drugs are tested in three phases of clinical trials prior to drug approval. These trials ensure the drug is safe and effective.